GMR Solutions Inc. risk profile
42 Elevated one input has moved against it
Measured 1 September 2026 from GMRS's filed statements. Recomputed nightly.
42 (Elevated), driven by Market expectation at 58, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 58 | Elevated | Volatile | One-year price volatility — 68.0% |
| Operating pressure | 34 | Normal | Worsening | Costs outgrowing revenue — -0.2 percentage points |
| Cash conversion | 25 | Normal | Easing | Capital spending against operating cash — 0.40x |
| Leverage and coverage | 57 | Elevated | Easing | Net debt to EBITDA — 4.46x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for GMR Solutions Inc.